NextCure, Inc. (NXTC) AI Stock Summary

Snapshot

NextCure is a clinical-stage biotech burning cash rapidly with no revenue. The structured data shows a cash runway of just 1.5 months, indicating immediate liquidity concerns despite a balance sheet listing $41.8M in cash. FY 2025 free cash flow was negative $49.6M, and the share count increased 22% over the last year. The company recently announced a merger that effectively changes its business focus and dilutes current shareholders to roughly 1% of the new entity.

What's Happening Right Now

• Tue 14th Jul '26 · Merger: NextCure agreed to merge with privately-held Avere Therapeutics, changing its name to Avere Therapeutics and ticker to AVRX, with current NextCure stockholders retaining approximately 1.21% of the combined company.
• Mon 1st Jun '26 · Clinical data: NextCure reported positive Phase 1 dose escalation data for SIM0505 at ASCO 2026, showing a 55% objective response rate in gynecologic cancers and 52.9% in ovarian cancer.
• Fri 8th May '26 · Business update: The company announced FDA Fast Track designation for SIM0505 for platinum-resistant ovarian cancer and reported Q1 cash of $29.7 million, sufficient to fund operations into the first half of 2027.

Ownership

Institutions hold 65.1% of shares, while insiders hold 0.0%.

Bottom Line

The pending merger with Avere Therapeutics is the dominant story here. Current NextCure shareholders are set to retain roughly 1.2% of the combined company, meaning the stock they own today effectively ceases to exist in its current form. Financially, the company faces a severe cash crunch with a runway of only 1.5 months according to the structured data. The clinical data for SIM0505 was positive, but the financing structure of the merger overrides it for existing investors.